Cargando…

Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization

BACKGROUND: There has been increasing use of extracorporeal membrane oxygenation (ECMO) as bridge to heart transplant (orthotopic heart transplant [OHT]) or left ventricular assist device (LVAD) over the last decade. We aimed to provide insights on the population, outcomes, and predictors for the se...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastoris, Ioannis, Tonna, Joseph E., Hu, Jinxiang, Sauer, Andrew J., Haglund, Nicholas A., Rycus, Peter, Wang, Yu, Wallisch, William J., Abicht, Travis O., Danter, Matthew R., Tedford, Ryan J., Fang, James C., Shah, Zubair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763251/
https://www.ncbi.nlm.nih.gov/pubmed/34879706
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.121.008777
_version_ 1784633898190241792
author Mastoris, Ioannis
Tonna, Joseph E.
Hu, Jinxiang
Sauer, Andrew J.
Haglund, Nicholas A.
Rycus, Peter
Wang, Yu
Wallisch, William J.
Abicht, Travis O.
Danter, Matthew R.
Tedford, Ryan J.
Fang, James C.
Shah, Zubair
author_facet Mastoris, Ioannis
Tonna, Joseph E.
Hu, Jinxiang
Sauer, Andrew J.
Haglund, Nicholas A.
Rycus, Peter
Wang, Yu
Wallisch, William J.
Abicht, Travis O.
Danter, Matthew R.
Tedford, Ryan J.
Fang, James C.
Shah, Zubair
author_sort Mastoris, Ioannis
collection PubMed
description BACKGROUND: There has been increasing use of extracorporeal membrane oxygenation (ECMO) as bridge to heart transplant (orthotopic heart transplant [OHT]) or left ventricular assist device (LVAD) over the last decade. We aimed to provide insights on the population, outcomes, and predictors for the selection of each therapy. METHODS: Using the Extracorporeal Life Support Organization Registry between 2010 and 2019, we compared in-hospital mortality and length of stay, predictors of OHT versus LVAD, and predictors of in-hospital mortality for patients with cardiogenic shock that were bridged with ECMO to OHT or LVAD. One hundred sixty-seven patients underwent LVAD versus 234 patients who underwent OHT. RESULTS: The overall use of ECMO has increased from 1.7% in 2010 to 22.2% in 2019. Mortality was similar between groups (LVAD: 28.7% versus OHT: 29.1%) while length of stay was longer for OHT (LVAD: 49.6 versus OHT: 59.5 days, P=0.05). Factors associated with OHT included prior transplant (odds ratio [OR]=31.26 [CI, 3.84–780.5]), use of a temporary pacemaker (OR=6.5 [CI, 1.39–50.15]), and increased use of inotropes on ECMO (OR=3.77 [CI, 1.39–11.07]), whereas LVAD use was associated with weight (OR=0.98 [CI, 0.97–0.99]), cardiogenic shock presentation (OR=0.40 [CI, 0.21–0.78]), previous LVAD (OR=0.01 [CI, 0.0001–0.22]), respiratory failure (OR=0.28 [CI, 0.11–0.70]), and milrinone infusion (OR=0.32 [CI, 0.15–0.67]). Older age (OR=1.07 [CI, 1.02–1.12]), cannulation bleeding (OR=26.1 [CI, 4.32–221.3]), and surgical bleeding (OR=6.7 [CI, 1.26–39.9]) in patients receiving LVAD and respiratory failure (OR=5 [CI, 1.17–23.1]) and continuous renal replacement therapy (OR=3.82 [CI, 1.28–11.9]) in patients receiving OHT were associated with increased mortality. CONCLUSIONS: ECMO use as a bridge to advanced therapies has increased over time, with more patients undergoing LVAD than OHT. Mortality was equal between the 2 groups while length of stay was longer for OHT.
format Online
Article
Text
id pubmed-8763251
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-87632512022-01-21 Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization Mastoris, Ioannis Tonna, Joseph E. Hu, Jinxiang Sauer, Andrew J. Haglund, Nicholas A. Rycus, Peter Wang, Yu Wallisch, William J. Abicht, Travis O. Danter, Matthew R. Tedford, Ryan J. Fang, James C. Shah, Zubair Circ Heart Fail Original Articles BACKGROUND: There has been increasing use of extracorporeal membrane oxygenation (ECMO) as bridge to heart transplant (orthotopic heart transplant [OHT]) or left ventricular assist device (LVAD) over the last decade. We aimed to provide insights on the population, outcomes, and predictors for the selection of each therapy. METHODS: Using the Extracorporeal Life Support Organization Registry between 2010 and 2019, we compared in-hospital mortality and length of stay, predictors of OHT versus LVAD, and predictors of in-hospital mortality for patients with cardiogenic shock that were bridged with ECMO to OHT or LVAD. One hundred sixty-seven patients underwent LVAD versus 234 patients who underwent OHT. RESULTS: The overall use of ECMO has increased from 1.7% in 2010 to 22.2% in 2019. Mortality was similar between groups (LVAD: 28.7% versus OHT: 29.1%) while length of stay was longer for OHT (LVAD: 49.6 versus OHT: 59.5 days, P=0.05). Factors associated with OHT included prior transplant (odds ratio [OR]=31.26 [CI, 3.84–780.5]), use of a temporary pacemaker (OR=6.5 [CI, 1.39–50.15]), and increased use of inotropes on ECMO (OR=3.77 [CI, 1.39–11.07]), whereas LVAD use was associated with weight (OR=0.98 [CI, 0.97–0.99]), cardiogenic shock presentation (OR=0.40 [CI, 0.21–0.78]), previous LVAD (OR=0.01 [CI, 0.0001–0.22]), respiratory failure (OR=0.28 [CI, 0.11–0.70]), and milrinone infusion (OR=0.32 [CI, 0.15–0.67]). Older age (OR=1.07 [CI, 1.02–1.12]), cannulation bleeding (OR=26.1 [CI, 4.32–221.3]), and surgical bleeding (OR=6.7 [CI, 1.26–39.9]) in patients receiving LVAD and respiratory failure (OR=5 [CI, 1.17–23.1]) and continuous renal replacement therapy (OR=3.82 [CI, 1.28–11.9]) in patients receiving OHT were associated with increased mortality. CONCLUSIONS: ECMO use as a bridge to advanced therapies has increased over time, with more patients undergoing LVAD than OHT. Mortality was equal between the 2 groups while length of stay was longer for OHT. Lippincott Williams & Wilkins 2021-12-09 /pmc/articles/PMC8763251/ /pubmed/34879706 http://dx.doi.org/10.1161/CIRCHEARTFAILURE.121.008777 Text en © 2021 The Authors. https://creativecommons.org/licenses/by-nc-nd/4.0/Circulation: Heart Failure is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
spellingShingle Original Articles
Mastoris, Ioannis
Tonna, Joseph E.
Hu, Jinxiang
Sauer, Andrew J.
Haglund, Nicholas A.
Rycus, Peter
Wang, Yu
Wallisch, William J.
Abicht, Travis O.
Danter, Matthew R.
Tedford, Ryan J.
Fang, James C.
Shah, Zubair
Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization
title Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization
title_full Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization
title_fullStr Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization
title_full_unstemmed Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization
title_short Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization
title_sort use of extracorporeal membrane oxygenation as bridge to replacement therapies in cardiogenic shock: insights from the extracorporeal life support organization
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763251/
https://www.ncbi.nlm.nih.gov/pubmed/34879706
http://dx.doi.org/10.1161/CIRCHEARTFAILURE.121.008777
work_keys_str_mv AT mastorisioannis useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization
AT tonnajosephe useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization
AT hujinxiang useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization
AT sauerandrewj useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization
AT haglundnicholasa useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization
AT rycuspeter useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization
AT wangyu useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization
AT wallischwilliamj useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization
AT abichttraviso useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization
AT dantermatthewr useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization
AT tedfordryanj useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization
AT fangjamesc useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization
AT shahzubair useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization